small molecule

VRAYLAR

CARIPRAZINE HYDROCHLORIDE

Loss of exclusivityMarch 2030latest FDA-listed patent expiry

CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand name	VRAYLAR
Active ingredient	CARIPRAZINE HYDROCHLORIDE
Strength	EQ 3MG BASE
Dosage form	CAPSULE
Route	ORAL
Modality	Small molecule
FDA approval	September 2015
Marketing status	RX

Listed patents

Patent	Expires	Type
7737142*PED	March 2030	—
RE49110*PED	January 2030	—
RE49302*PED	January 2030	—
7737142	September 2029	substance, product
RE49302	July 2029	use U-3503
RE49110	July 2029	use U-3503
7943621*PED	June 2029	—
7943621	December 2028	substance, product

Regulatory exclusivity

Code	Expires
PED	June 2029
M-14	December 2028
NPP	December 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from AbbVie Inc.